

2026/10/6

RIBOMIC Announces Interim Report on the Phase 2 Long-Term Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia

TOKYO, October 6, 2026 - RIBOMIC, Inc. (TYO:4591), a clinical-stage pharmaceutical company specializing in aptamer therapeutics, has announced today the interim report on the phase 2 long-term clinical trial of umedaptanib pegol (anti-FGF2 aptamer) in paediatric patients with achondroplasia.


In this phase 2 clinical trial of umedaptanib pegol for achondroplasia, the following 11 pediatric patients transitioned to the long-term administration phase and continued receiving the drug. We are pleased to report that interim data from this trial have now been obtained, confirming the sustained efficacy in responders.

- Cohort 1: 5 patients in the group receiving weekly subcutaneous administration of 0.3 mg/kg of umedaptanib pegol
- Cohort 2: 6 patients in the group receiving subcutaneous administration of 0.6 mg/kg of umedaptanib pegol once every two weeks

Among the 7 patients who are still participating in the clinical trial, more than two and a half years have passed since the start of administration in Cohort 1, and more than one and a half years have passed in Cohort 2. In addition, the trends in annualized growth velocity (AGV; cm/year) compared to pre-treatment levels (observation study) are shown below for the nine patients who received umedaptanib pegol continuously for at least one year, including those who discontinued treatment.

In the four pediatric patients whose growth velocity increased markedly over a six-month period, it was confirmed that the growth-promoting effect of umedaptanib pegol persisted. In contrast, in the five patients who did not respond or did not show a marked effect, no improvement in responsiveness was observed with continued administration during the study period. The AGV in responsive patients exceeded the average growth rate (+1.5 to 1.7 cm/year) of vosoritide (manufactured by BioMarin), which is currently approved as an achondroplasia treatment. Furthermore, no safety concerns were identified during these

long-term administration trials.



Of the patients who transitioned to the long-term trial described above, four—including those who did not respond—have discontinued the trial; four are continuing with the same dosage regimen; and three have switched to a once-weekly subcutaneous administration of 1.0 mg/kg of umedaptanib pegol following a change in dosage regimen. We will continue to closely monitor the growth-promoting effects resulting from the increase in the 1.0 mg/kg dose of umedaptanib pegol.

This matter will have no impact on financial results for the fiscal year ending March 2027.

Note: Annualized Growth Velocity (AGV) refers to the same metric as Annualized Height Velocity (AHV), which the Company has used in timely disclosures and other communications to date. In this document, we are using the AGV notation commonly employed in academic literature and other sources related to achondroplasia.

[About Umedaptanib Pegol]

Umedaptanib pegol is the international nonproprietary name (INN) for RBM-007. As an aptamer (nucleic acid medicine) that powerfully inhibits the function of fibroblast growth factor 2 (FGF2), it is expected to become a fundamental treatment directly targeting the pathogenesis of achondroplasia. This drug has received orphan drug designation from the Ministry of Health, Labour and Welfare (MHLW) of Japan.

[About Achondroplasia]

Achondroplasia is a disease caused by a mutation in the fibroblast growth factor receptor 3

(FGFR3) gene. This mutation makes FGFR3 more easily activated, leading to excessive influx of FGF signals. This inhibits the normal development of cartilage and other tissues, resulting in short stature accompanied by limb shortening. It is a rare disease with an incidence of approximately 1 in 25,000 newborns and is designated as an intractable disease. The development of effective new drugs is urgently needed.

Please visit the RIBOMIC website for more information.

<https://www.ribomic.com/eng/>

Forward-Looking Statements This announcement contains forward-looking statements relating to current plans, estimates, strategies, belief and the future performance of Company. These statements are based on Company's current expectations in light of the information and assumptions currently available so that Company does not promise the realization and these expectations may differ materially from those discussed in the forward-looking statements. These factors include, but not limited to, i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, ii) currency exchange rate fluctuations, iii) claims and concerns on the product safety and efficacy, iv) completion and News Release discontinuation of clinical trials, v) infringement of Company's intellectual property rights by third parties. Information on pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice.

"RIBOMIC," "RiboART system" and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.

Contacts for inquiries or additional information: RIBOMIC Inc.
ir.inquiry@ribomic.com